{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:58:00Z","timestamp":1792425480975,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8\u2013negative\/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm\u2013driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have \u201coligocentric\u201d lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014391","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T20:08:21Z","timestamp":1739563701000},"page":"1952-1965","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-1411","authenticated-orcid":false,"given":"Sheila K.","family":"Pierson","sequence":"first","affiliation":[{"name":"1Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0652-5791","authenticated-orcid":false,"given":"Joshua D.","family":"Brandstadter","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-9735","authenticated-orcid":false,"given":"Drew A.","family":"Torigian","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-468X","authenticated-orcid":false,"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[{"name":"4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-1950","authenticated-orcid":false,"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-8375","authenticated-orcid":false,"given":"Daisy","family":"Alapat","sequence":"additional","affiliation":[{"name":"6Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-661X","authenticated-orcid":false,"given":"Corey","family":"Casper","sequence":"additional","affiliation":[{"name":"7Access to Advanced Health Institute, Seattle, WA"},{"name":"8Departments of Medicine and Global Health, University of Washington, Seattle, WA"},{"name":"9Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-8638","authenticated-orcid":false,"given":"Amy","family":"Chadburn","sequence":"additional","affiliation":[{"name":"10Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-9932","authenticated-orcid":false,"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4484-9319","authenticated-orcid":false,"given":"Alexander","family":"Foss\u00e5","sequence":"additional","affiliation":[{"name":"13Department of Oncology, Oslo University Hospital, Oslo, Norway"},{"name":"14K.G. Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1082-8093","authenticated-orcid":false,"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"15ICH Hamburg Study Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5296-7518","authenticated-orcid":false,"given":"Makoto","family":"Ide","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Takamatsu Red Cross Hospital, Takamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-2603","authenticated-orcid":false,"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"18Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8981-2931","authenticated-orcid":false,"given":"Sunita","family":"Nasta","sequence":"additional","affiliation":[{"name":"19Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-6013","authenticated-orcid":false,"given":"Jos\u00e9-Tom\u00e1s","family":"Navarro","sequence":"additional","affiliation":[{"name":"20Department of Hematology-Laboratory, Institut Catal\u00e0 d'Oncologia-Germans Trias i Pujol Hospital, Josep Carreras Leukaemia Research Institute, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"21Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-7138","authenticated-orcid":false,"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[{"name":"22Department of Clinical Immunology, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6774-2714","authenticated-orcid":false,"given":"Mateo Sarmiento","family":"Bustamante","sequence":"additional","affiliation":[{"name":"1Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0160-8910","authenticated-orcid":false,"given":"Saishravan","family":"Shyamsundar","sequence":"additional","affiliation":[{"name":"1Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Streetly","sequence":"additional","affiliation":[{"name":"23Clinical Haematology, Guy\u2019s Hospital, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"24Department of Haematological Medicine, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-4268","authenticated-orcid":false,"given":"Raymond S. M.","family":"Wong","sequence":"additional","affiliation":[{"name":"25Sir Y.K. Pao Centre for Cancer and Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"26Department of Haematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-2867","authenticated-orcid":false,"given":"Megan S.","family":"Lim","sequence":"additional","affiliation":[{"name":"27Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3519-0409","authenticated-orcid":false,"given":"Gordan","family":"Srkalovic","sequence":"additional","affiliation":[{"name":"28University of Michigan Health-Sparrow Herbert-Herman Cancer Center, Lansing, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"29Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-8184","authenticated-orcid":false,"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"1Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"4","key":"2025042208513571700_bib1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"issue":"16","key":"2025042208513571700_bib2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025042208513571700_bib3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2025042208513571700_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2025042208513571700_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"2025042208513571700_bib6","first-page":"2196","article-title":"Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease","volume":"109","author":"Bustamante","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"2025042208513571700_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3960\/jslrt.22011","article-title":"Idiopathic plasmacytic lymphadenopathy: a conceptual history along with a translation of the original Japanese article published in 1980","volume":"62","author":"Takeuchi","year":"2022","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"18","key":"2025042208513571700_bib8","doi-asserted-by":"crossref","first-page":"10301","DOI":"10.3390\/ijms231810301","article-title":"Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease","volume":"23","author":"Nishikori","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2025042208513571700_bib9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"key":"2025042208513571700_bib10","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.lanwpc.2023.100720","article-title":"A\u00a0national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang","year":"2023","journal-title":"Lancet Reg. Heal. \u2013 West. Pacific 0"},{"issue":"22","key":"2025042208513571700_bib11","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease","volume":"132","author":"Fajgenbaum","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2025042208513571700_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas","volume":"2","author":"Nagy","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2025042208513571700_bib13","doi-asserted-by":"crossref","first-page":"e0218660","DOI":"10.1371\/journal.pone.0218660","article-title":"Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease","volume":"14","author":"Nabel","year":"2019","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2025042208513571700_bib14","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1182\/blood-2023-188991","article-title":"Exploratory analyses of lymph node tissue, serum, and peripheral blood mononuclear cells do not reveal pathogen signatures in idiopathic multicentric Castleman disease","volume":"142","author":"Miller","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025042208513571700_bib15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Brief report: alleviation of systemic manifestations of Castleman\u2019s disease by monoclonal anti-interleukin-6 antibody","volume":"330","author":"Beck","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025042208513571700_bib16","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"issue":"23","key":"2025042208513571700_bib17","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2025042208513571700_bib18","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025042208513571700_bib19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB mutations in unicentric Castleman disease","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"2025042208513571700_bib20","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International, evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2025042208513571700_bib21","doi-asserted-by":"crossref","first-page":"E334","DOI":"10.1002\/ajh.27065","article-title":"Ongoing symptoms following complete surgical excision in unicentric Castleman disease","volume":"98","author":"Sarmiento Bustamante","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2025042208513571700_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2020003607","article-title":"UCD with MCD-like inflammatory state: surgical excision is highly effective","volume":"5","author":"Zhang","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025042208513571700_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.clml.2020.05.002","article-title":"Excellent outcomes with surgery or radiotherapy in the management of Castleman disease including a case of oligocentric disease","volume":"20","author":"Beckham","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025042208513571700_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hoc.2017.09.008","article-title":"Treatment of idiopathic Castleman disease","volume":"32","author":"van Rhee","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"2025042208513571700_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000526640","article-title":"Recent advances in Castleman disease","volume":"45","author":"Hoffmann","year":"2022","journal-title":"Oncol Res Treat"},{"key":"2025042208513571700_bib26","first-page":"529","article-title":"The consensus of the diagnosis and treatment of Castleman disease in China (2021)","volume":"42","author":"Hematology Committee of Chinese Medical Association; Hematological Oncology Committee of China Anti-Cancer Association; China Castleman Disease Network (CCDN)","year":"2021","journal-title":"Chinese J. Hematol"},{"issue":"11","key":"2025042208513571700_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman\u2019s disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2025042208513571700_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3960\/jslrt.21036","article-title":"Historical and pathological overview of Castleman disease","volume":"62","author":"Nishimura","year":"2022","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"9","key":"2025042208513571700_bib29","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.xcrm.2020.100158","article-title":"ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder","volume":"1","author":"Pierson","year":"2020","journal-title":"Cell Rep Med"},{"issue":"11","key":"2025042208513571700_bib30","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"12","key":"2025042208513571700_bib31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/ajh.25992","article-title":"Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease","volume":"95","author":"Fajgenbaum","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2025042208513571700_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-020-1345-5","article-title":"The French paediatric cohort of Castleman disease: a retrospective report of 23 patients","volume":"15","author":"Borocco","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"2025042208513571700_bib33","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMcpc2115849","article-title":"Case 16-2022: a 55-year-old man with fevers, night sweats, and a mediastinal mass","volume":"386","author":"Fajgenbaum","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025042208513571700_bib34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20 years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br J Haematol"},{"issue":"19","key":"2025042208513571700_bib35","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1952\/2369326\/blooda_adv-2024-014391-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1952\/2369326\/blooda_adv-2024-014391-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:51:50Z","timestamp":1745326310000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1952\/535588\/Characterizing-the-heterogeneity-of-Castleman"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014391","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}